Ravidasvir

Ravidasvir
Clinical data
Other namesPPI-668
ATC code
Identifiers
  • (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC42H50N8O6
Molar mass762.912 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1
  • Key:LCHMHYPWGWYXEL-ZYADHFCISA-N

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.

It is on the World Health Organization's List of Essential Medicines.

On December 11, 2024 it was approved in Russia under the trade name Konesko for the treatment of chronic hepatitis C in adult patients (only in combination with sofosbuvir). In the pivotal clinical trial STORM-C-1, the majority of patients were infected with HCV genotypes 1 or 3. Data from this study in patients with HCV genotypes 2 and 6 are limited, and data on patients with genotypes 4 or 5 are not available.

Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.

References

  1. ↑ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
  2. ↑ The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  3. ↑ "Unified registry of apruval drugs EAEU" [Unified registry of apruval drugs of the Eurasian Economic Union]. Единый реестр зарегистрированных лекарственных средств Евразийского экономического союза (in Russian).
  4. ↑ "Konesko (ravidasvir) Film-coated Tablets. Full Prescribing Information". Russian State Register of Medicines (in Russian). HTC «Chemrar». Retrieved 14 March 2025.
  5. ↑ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.
  6. ↑ Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.
  7. ↑ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).
  8. ↑ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.